RhumbLine Advisers’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.74M Sell
83,768
-9,186
-10% -$331K ﹤0.01% 1781
2026
Q1
$3.29M Buy
92,954
+1,483
+2% +$60.3K ﹤0.01% 1606
2025
Q4
$3.71M Sell
91,471
-5,400
-6% -$235K ﹤0.01% 1549
2025
Q3
$4.56M Sell
96,871
-2,733
-3% -$142K ﹤0.01% 1487
2025
Q2
$5.19M Buy
99,604
+5,614
+6% +$308K ﹤0.01% 1398
2025
Q1
$5.68M Sell
93,990
-334
-0.4% -$21.5K 0.01% 1292
2024
Q4
$6.46M Buy
94,324
+3,486
+4% +$243K 0.01% 1290
2024
Q3
$6.53M Sell
90,838
-2,402
-3% -$169K 0.01% 1274
2024
Q2
$6.46M Buy
93,240
+590
+0.6% +$43K 0.01% 1250
2024
Q1
$7.42M Sell
92,650
-2,326
-2% -$207K 0.01% 1204
2023
Q4
$10.4M Sell
94,976
-3,979
-4% -$411K 0.01% 1035
2023
Q3
$9.98M Buy
98,955
+793
+0.8% +$91.1K 0.01% 991
2023
Q2
$13.3M Buy
98,162
+1,257
+1% +$153K 0.01% 869
2023
Q1
$10.1M Buy
96,905
+3,732
+4% +$361K 0.01% 962
2022
Q4
$8.26M Buy
93,173
+2,912
+3% +$242K 0.01% 1031
2022
Q3
$7.24M Buy
90,261
+5,392
+6% +$509K 0.01% 1055
2022
Q2
$8.13M Buy
84,869
+3,335
+4% +$400K 0.01% 1002
2022
Q1
$12.1M Buy
81,534
+4,798
+6% +$670K 0.02% 859
2021
Q4
$10.9M Sell
76,736
-671
-0.9% -$95K 0.01% 948
2021
Q3
$10.1M Sell
77,407
-11,378
-13% -$1.49M 0.01% 943
2021
Q2
$12.2M Buy
88,785
+494
+0.6% +$67.6K 0.02% 887
2021
Q1
$11.5M Buy
88,291
+1,356
+2% +$163K 0.02% 899
2020
Q4
$9.74M Buy
86,935
+3,522
+4% +$333K 0.01% 941
2020
Q3
$6.56M Sell
83,413
-10,309
-11% -$841K 0.01% 993
2020
Q2
$6.75M Sell
93,722
-4,181
-4% -$291K 0.01% 1005
2020
Q1
$5.61M Buy
97,903
+649
+0.7% +$59.9K 0.01% 955
2019
Q4
$10.9M Buy
97,254
+6,072
+7% +$647K 0.02% 786
2019
Q3
$8.77M Buy
91,182
+5,598
+7% +$526K 0.02% 843
2019
Q2
$7.32M Buy
85,584
+1,841
+2% +$151K 0.01% 966
2019
Q1
$6.97M Buy
83,743
+1,057
+1% +$76.8K 0.01% 977
2018
Q4
$5.31M Buy
82,686
+13,198
+19% +$903K 0.01% 1071
2018
Q3
$5.5M Hold
69,488
0.01% 1046
2018
Q2
$5.09M Sell
69,488
-2,433
-3% -$165K 0.01% 1082
2018
Q1
$4.55M Buy
71,921
+63
+0.1% +$3.76K 0.01% 1098
2017
Q4
$3.66M Buy
71,858
+6,193
+9% +$323K 0.01% 1257
2017
Q3
$3.44M Buy
65,665
+936
+1% +$47K 0.01% 1264
2017
Q2
$3.3M Sell
64,729
-276
-0.4% -$13.7K 0.01% 1257
2017
Q1
$2.89M Buy
65,005
+13,928
+27% +$599K 0.01% 1343
2016
Q4
$2.26M Sell
51,077
-1,131
-2% -$48.1K 0.01% 1372
2016
Q3
$2.09M Buy
52,208
+1,190
+2% +$50.5K 0.01% 1365
2016
Q2
$2.44M Sell
51,018
-7,679
-13% -$325K 0.01% 1218
2016
Q1
$2.46M Buy
58,697
+3,925
+7% +$154K 0.01% 1226
2015
Q4
$2.41M Buy
54,772
+1,555
+3% +$67.5K 0.01% 1230
2015
Q3
$2.54M Buy
53,217
+1,995
+4% +$110K 0.01% 1185
2015
Q2
$2.98M Sell
51,222
-625
-1% -$33.7K 0.01% 1147
2015
Q1
$2.62M Buy
51,847
+700
+1% +$34.3K 0.01% 1223
2014
Q4
$2.3M Buy
51,147
+505
+1% +$21.2K 0.01% 1256
2014
Q3
$1.87M Buy
50,642
+200
+0.4% +$7.93K 0.01% 1366
2014
Q2
$2.23M Sell
50,442
-1,626
-3% -$73.7K 0.01% 1296
2014
Q1
$2.26M Sell
52,068
-1,560
-3% -$69.5K 0.01% 1269
2013
Q4
$2.28M Sell
53,628
-2,650
-5% -$101K 0.01% 1293
2013
Q3
$1.91M Sell
56,278
-749
-1% -$24.4K 0.01% 1383
2013
Q2
$1.78M Buy
+57,027
New +$1.85M 0.01% 1383

Other funds holding CNMD

RhumbLine Advisers's CNMD Position: Q2 2026 in Review

RhumbLine Advisers reduced its CONMED (CNMD) stake by 9.9% in Q2 2026, selling an estimated $331K and leaving 83,768 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

RhumbLine Advisers first reported a position in CNMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.3M in Q2 2023. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • RhumbLine Advisers held 83,768 shares of CONMED worth $2.74M as of Q2 2026.
  • RhumbLine Advisers sold 9,186 CONMED shares in Q2 2026, an estimated $331K.
  • CONMED made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1781 holding.
  • RhumbLine Advisers first reported a position in CONMED in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's CONMED position peaked at $13.3M in Q2 2023.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.